Recombinant GroES in combination with CpG oligodeoxynucleotides protects mice against infection Free

Abstract

The gene of strain 485 was cloned and expressed in and the recombinant GroES protein was purified by affinity chromatography. The GroES preparation showed high purity by electrophoresis and immunoblotting. Immuno-electron microscopy showed that GroES was located both in the cytoplasm and on the surface of the mycobacterial cells and thus is readily available to interact with the host immune system. BALB/c mice were immunised intranasally with recombinant GroES, alone or in combination with a synthetic oligodeoxynucleotide containing unmethylated CpG motifs, and tested for protection against infection with . Neither GroES nor CpG alone provided any protection against subsequent challenge with , whereas a combination of the two significantly protected the lungs and spleen against colonisation by after intranasal challenge with a low dose of the organism. This indicates that intranasal administration of GroES and CpG oligodeoxynucleotides increases the resistance of BALB/c mice to infection.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/0022-1317-51-12-1071
2002-12-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jmm/51/12/1071.html?itemId=/content/journal/jmm/10.1099/0022-1317-51-12-1071&mimeType=html&fmt=ahah

References

  1. Inderlied CB, Kemper CA, Bermudez LEM. The Mycobacterium avium complex. Clin Microbiol Rev 1993; 6:266–310
    [Google Scholar]
  2. Horshburg CR. Epidemiology of Mycobacterium avium complex. In Korvick JA, Benson CA. eds Mycobacterium avium complex infection: progress in research and treatment M. Dekker 19961–22
    [Google Scholar]
  3. Middleton AM, Chadwick MV, Nicholson AG. et al. The role of Mycobacterium avium complex fibronectin attachment protein in adherence to the human respiratory mucosa. Mol Microbiol 2000; 38:381–391 [CrossRef]
    [Google Scholar]
  4. von Reyn CF, Waddel RD, Eaton T. et al. Isolation of Mycobacterium avium complex from water in the United States, Finland, Zaire and Kenya. J Clin Microbiol 1993; 31:3227–3230
    [Google Scholar]
  5. Georgopoulos C, Welch WJ. Role of the major heat shock proteins as molecular chaperones. Annu Rev Cell Biol 1993; 9:601–634 [CrossRef]
    [Google Scholar]
  6. Cobb AJ, Frothingham R. The GroES antigens of Mycobacterium avium and Mycobacterium paratuberculosis . Vet Microbiol 1999; 67:31–35 [CrossRef]
    [Google Scholar]
  7. Verbon A, Kuijper S, Jansen HM, Speelman P, Kolk AH. Antigens in culture supernatant of Mycobacterium tuberculosis : epitopes defined by monoclonal and human antibodies. J Gen Microbiol 1990; 136:955–964 [CrossRef]
    [Google Scholar]
  8. Orme IM, Miller ES, Roberts AD. et al. T lymphocytes mediating protection and cellular cytolysis during the course of Mycobacterium tuberculosis infection.Evidence for different kinetics and recognition of a wide spectrum of protein antigens. J Immunol 1992; 148:189–196
    [Google Scholar]
  9. Coates ARM. Immunological aspects of chaperonins. In Ellis RJ. ed The chaperonins. Academic Press 1996267–296
    [Google Scholar]
  10. Gelber RH, Mehra V, Bloom B. et al. Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads. Infect Immun 1994; 10:4250–4255
    [Google Scholar]
  11. Ferrero RL, Thiberge JM, Kansau I, Wuscher N, Huerre M, Labigne A. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci USA 1995; 92:6499–6503 [CrossRef]
    [Google Scholar]
  12. Scheule RK. The role of CpG motifs in immunostimulation and gene therapy. Adv Drug Deliv Rev 2000; 44:119–134 [CrossRef]
    [Google Scholar]
  13. McCluskie MJ, Davis HL. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine 2001; 19:413–422
    [Google Scholar]
  14. McCluskie MJ, Davis HL. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol 1998; 161:4463–4466
    [Google Scholar]
  15. Fattorini L, Xiao Y, Ausiello CM. et al. Late acquisition of hyporesponsiveness to lipopolysaccharide by Mycobacterium avium -infected human macrophages in producing tumor necrosis factor-alpha but not interleukin-1 beta and -6. J Infect Dis 1996; 173:1030–1034 [CrossRef]
    [Google Scholar]
  16. Ausubel FM, Brent R, Kingston RE. et al . Current protocols in molecular biology New York: John Wiley & Sons; 1995
    [Google Scholar]
  17. Mande SC, Mehra V, Bloom BR, Hol WGJ. Structure of the heat shock protein chaperonin-10 of M. leprae . Science 1996; 271:203–207 [CrossRef]
    [Google Scholar]
  18. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA; 1977; 745463–5467 [CrossRef]
  19. Qiagen. The Qia expressionist , 3rd edn. Hilden, Germany, Qiagen: 1997
    [Google Scholar]
  20. Wagner B, Fattorini L, Wagner M. et al. Antigenic properties and immunoelectron microscopic localization of Mycobacterium fortuitum beta-lactamase. Antimicrob Agents Chemother 1995; 39:739–745 [CrossRef]
    [Google Scholar]
  21. Molinari A, Calcabrini A, Meschini S. et al. Detection of P-glycoprotein in the Golgi apparatus of drug-untreated human melanoma cells. Int J Cancer 1998; 75:885–893 [CrossRef]
    [Google Scholar]
  22. von Hunolstein C, Mariotti S, Teloni R. et al. The adjuvant effect of synthetic oligodeoxynucleotide containing CpG motif converts the anti- Haemophilus influenzae type b glycoconjugates into efficient anti-polysaccharide and anti-carrier polyvalent vaccines. Vaccine 2001; 19:3058–3066 [CrossRef]
    [Google Scholar]
  23. Kong TH, Coates ARM, Butcher PD, Hickman CJ, Shinnick TM. M. tuberculosis expresses two chaperonin-60 homologs. Proc Natl Acad Sci USA 1993; 90:2608–2612 [CrossRef]
    [Google Scholar]
  24. Rinke de Wit TF, Bekelie S, Osland A. et al. Mycobacteria contain two groEL genes: the second Mycobacterium leprae groEL gene is arranged in an operon with groES . Mol Microbiol 1992; 6:1995–2007 [CrossRef]
    [Google Scholar]
  25. Zuber U, Schumann W. CIRCE, a novel heat shock element involved in regulation of heat shock operon dnaK of Bacillus subtilis . J Bacteriol 1994; 176:1359–1363
    [Google Scholar]
  26. Hecker M, Schumann W, Volker U. Heat-shock and general stress response in Bacillus subtilis . Mol Microbiol 1996; 19:417–428 [CrossRef]
    [Google Scholar]
  27. Schon U, Schumann W. Construction of His6-tagging vectors allowing single-step purification of GroES and other polypeptides produced in Bacillus subtilis . Gene 1994; 147:91–94 [CrossRef]
    [Google Scholar]
  28. Lewthwaite J, Skinner A, Henderson B. Are molecular chaperones microbial virulence factors? Trends Microbiol ; 1998; 6426–428 [CrossRef]
  29. Lowrie DB, Tascon RE, Bonato VL. et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999; 400:269–271 [CrossRef]
    [Google Scholar]
  30. Tighe H, Corr M, Roman R, Raz E. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol Today 1998; 19:89–97 [CrossRef]
    [Google Scholar]
  31. Jones TR, Obaldia N, Gramzinski RA. et al. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine 1999; 17:3065–3071 [CrossRef]
    [Google Scholar]
  32. Juffermans NP, Leemans JC, Florquin S. et al. CpG oligodeoxynucleotides enhance host defense during murine tuberculosis. Infect Immun 2000; 70:147–152
    [Google Scholar]
  33. Moldoveanu Z, Love-Homan L, Huang WQ, Krieg AM. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 1998; 16:1216–1224 [CrossRef]
    [Google Scholar]
  34. Freidag BL, Melton GB, Collins F. et al. CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis . Infect Immun 2000; 68:2948–2953 [CrossRef]
    [Google Scholar]
  35. Kelly BP, Furney SK, Jessen MT, Orme IM. Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis . Antimicrob Agents Chemother 1996; 40:2809–2812
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/0022-1317-51-12-1071
Loading
/content/journal/jmm/10.1099/0022-1317-51-12-1071
Loading

Data & Media loading...

Most cited Most Cited RSS feed